- Home
- NEN vs PRQR Comparison
NEN vs PRQR Comparison
Compare NEN & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEN
- PRQR
- Stock Information
- Founded
- NEN 1977
- PRQR 2012
- Country
- NEN United States
- PRQR Netherlands
- Employees
- NEN N/A
- PRQR N/A
- Industry
- NEN Building operators
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- NEN Real Estate
- PRQR Health Care
- Exchange
- NEN Nasdaq
- PRQR Nasdaq
- Market Cap
- NEN 282.1M
- PRQR 309.5M
- IPO Year
- NEN N/A
- PRQR 2014
- Fundamental
- Price
- NEN $82.00
- PRQR $2.56
- Analyst Decision
- NEN
- PRQR Strong Buy
- Analyst Count
- NEN 0
- PRQR 6
- Target Price
- NEN N/A
- PRQR $8.17
- AVG Volume (30 Days)
- NEN 32.0
- PRQR 296.6K
- Earning Date
- NEN 01-01-0001
- PRQR 03-12-2025
- Dividend Yield
- NEN 1.95%
- PRQR N/A
- EPS Growth
- NEN 67.91
- PRQR N/A
- EPS
- NEN 3.91
- PRQR N/A
- Revenue
- NEN $81,169,352.00
- PRQR $20,506,357.00
- Revenue This Year
- NEN N/A
- PRQR $210.18
- Revenue Next Year
- NEN N/A
- PRQR $33.25
- P/E Ratio
- NEN $20.99
- PRQR N/A
- Revenue Growth
- NEN 10.81
- PRQR 306.68
- 52 Week Low
- NEN $67.50
- PRQR $1.61
- 52 Week High
- NEN $84.00
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- NEN 48.09
- PRQR 56.93
- Support Level
- NEN $79.04
- PRQR $2.47
- Resistance Level
- NEN $82.74
- PRQR $2.67
- Average True Range (ATR)
- NEN 0.00
- PRQR 0.18
- MACD
- NEN -0.10
- PRQR 0.07
- Stochastic Oscillator
- NEN 74.75
- PRQR 83.58
About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating and selling real estate. The Partnership owns and operates various residential apartments, condominium units and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.